Eight $250,000 prizes will be awarded for key milestones in FSHD treatments and $8 million will be given for showing clinical ...
Arrakis' oral therapies targeting disease-driving RNA in myotonic dystrophy have shown promise in preclinical studies.
Columnist Shalom Lim describes a moving performance at the Enabling Lives Festival in Singapore, an example of the power of ...
The case is reported of a young woman who began having DMD symptoms before getting pregnant, allowing her to receive genetic ...
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
Columnist Robin Stemple knows his walker should help prevent falls, but it didn't work out that way on a simple maneuver to ...